Skip to content

Fluorescent virus for antiviral discovery & measurement of disinfection processes


Construction of autofluorescent vector and viruses for human and animal

NeoVirTech has developed a breakthrough technology to directly visualize and quantify in real time virus/viral vector infection and replication in living cells: the ANCHOR™ technology.

Several studies can be developed such as antiviral testing, inactivation solution testing or the development of decontamination devices (UV, ozone…) on different supports: cell lines, live human skin explants, surfaces (stainless steel, tissues, masks…) or even with materials that have a direct biocidal activity. We can test also your own material on request (fabric, leather, etc…).

We are constantly innovating to find the most appropriate solution to provide our customer state of the art virology testing.

Technology NeoVirtech

ANCHOR™ tagged viruses

Any viruses having a dsDNA phase can be tagged with ANCHOR™. Here you will find a list of viruses available for immediate use. We annually expand this collection with new viruses to quickly respond to human or veterinary threat.

Your virus of interest is not in this list? Do not hesitate to contact us, we will find a solution!

Virus replication NeoVirtech

Non-ANCHOR™ tagged viruses

We work on other non-ANCHOR tagged viruses on request.

As the ANCHOR system is not suitable to tag RNA viruses, we use classical virology readouts such as high throughput quantification of cytopathic effect, TCID50 or qPCR. Other readouts such as high throughput immunofluorescence are also available for some viruses.


Virus replication NeoVirtech

Our ANCHOR™ viruses are available in high-throughput imaging, making it a major tool for antiviral research and development. Combined with HCS microscopy and detection algorithm, it provides the fastest and the most robust techniques to discover new antivirals.

This allows us to rapidly set up the entire pre-clinical antiviral development pipeline:

  • drug discovery campaign (low, medium or high number of compounds), selectivity index calculation, hit sorting
  • hit validation and lead development
  • Determination of broad spectrum activities
  • Mechanism of Action
  • Target identification, resistant strain generation

Measurement of disinfection potential

NeoVirtech labs

We only score infectious viruses…

Our technology allows us to quickly calibrate and validate the development of disinfection devices. We can study all types of disinfection processes on our viruses and calculate the precise abatement to determine the optimal conditions of use.

We have already participated in the development of chemical, physical or radiative disinfection processes leading to the commercialization of innovative materials and decontamination devices. Contact us for more information.

Pr. Pierre Cordelier
We are fortunate to collaborate with NeoVirtech on several projects. They provide unique strategies to better address complex biological questions in live cells in real-time. With their help, we were able to visualize for the first time the behavior of oncolytic virus in preclinical models of pancreatic cancer, a disease with no cure. We obtained crystal clear experimental data that could definitely accelerate the transfer of therapeutic innovation to patient with this disease. I highly recommend Franck and team, as seeing is believing !
Pr. Pierre Cordelier
CRCT Inserm
Thursday, August 31, 2017
Dr. Philippe ErbsHead
Transgene SA is a biopharmaceutical company developing for more than 30 years innovative targeted-immunotherapies to answer unmet medical needs in the oncology and infectious disease fields. We were looking for a rapid and efficient solution to investigate the behavior of our products using high-resolution quantitative microscopy. NeoVirTech’s autofluorescence technology and screening platform allowed us to precisely visualize, understand and compare the behavior of our products directly using live cell microscopy techniques. The beauty and quality of the data they can generate open a new perspective for our activities, boosting up our research and validation processes. Thank you NeoVirTech for this ongoing precious collaboration.
Dr. Philippe ErbsHead
Oncolytic Virus Department. Transgene S.A, Illkirch Graffenstaden, France
Thursday, August 31, 2017